Profiles of emotion regulation in multiple sclerosis: Associations with depressive and anxiety symptoms
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Background. Emotion regulation is a multidimensional construct that is robustly linked to emotional disorders yet remains underexplored in multiple sclerosis (MS), with no studies to date addressing individual differences in emotion regulation difficulties in this population. To address this gap, the current study used latent profile analysis (LPA) to identify distinct profiles of emotion regulation difficulties in an MS sample. Methods. Participants were 259 people with MS (Mage = 42.79, 78.8% female). Participants completed an online survey measuring emotion regulation difficulties and symptoms of depression, generalised anxiety disorder (GAD), health anxiety, and posttraumatic stress disorder (PTSD). Emotion regulation was specified as the indicator variable in the LPA, with the additional measures of depression and anxiety utilised to validate the identified profiles.Results. Three emotion regulation profiles were identified: low impairment (n = 66, 25.48%) characterised by minimal difficulties regulating negative emotions across all domains; global dysregulation (n = 71, 27.41%) characterised by pronounced difficulties in all domains; and goal-impaired regulators (n = 122, 47.10%) characterised by distinct challenges maintaining goal-directed behaviours. Individuals in the global dysregulation profile endorsed the greatest symptom severity on measures of depression and PTSD but reported comparable levels of GAD and health anxiety relative to the goal-impaired regulators.Conclusion. People with MS exhibit distinct emotion regulation profiles, revealing critical subgroups with varying psychological needs. Tailoring psychological assessments and treatments to these profiles can enhance the management of depression and anxiety and potentially improve disease outcomes in people with MS.